Outcomes of a drug shortage requiring switching in patients with ulcerative colitis
World Journal of Gastrointestinal Pathophysiology · 12.04.2020 · 11 (2) · 32-42
DOI: 10.4291/wjgp.v11.i2.32 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Pathophysiology, erschienen am 12.04.2020. Verfasst von Daniel R van Langenberg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Eastern Health, Box Hill, Victoria 3128, Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Drug shortages are common yet their impact on patient care and their commercial ramifications has not been adequately researched. In Australia a shortage of balsalazide (2012-2013) necessitated substitution with alternative 5-aminosalicylate (5-ASA) formulations for ulcerative colitis (UC). AIM: To assess and compare the clinical and commercial sequelae of non-medical switching from balsalazide to another 5-ASA and/or return to balsalazide once supply resumed. METHODS: A prospective cohort study of patients on balsalazide for mild-moderate UC was conducted where, strictly due to the national shortage (November 2012- January 2013), were switched to alternative 5-ASA and/or then returned to balsalazide once supply resumed. Clinical (Partial Mayo), endoscopic (Mayo score) activity, adverse effects (to alternative 5-ASA) and percentage market share (of continuous 5-ASA users) from baseline (i.e., time of switching due to shortage) through to five years were assessed. RESULTS: Of 31 patients switched due to the shortage, 12 (38.7%) resumed balsalazide immediately once supply resumed, 8 (25.8%) prompted by adverse effects to the alternative 5-ASA used. Three patients (9.7%) had documented symptomatic improvement, 15 (48.4%) were unchanged and 13 (41.9%) had symptomatic worsening vs baseline (P < 0.01), after switching to an alternative 5-ASA. At 3 and 5y post switch, overall 26/31 (83.9%) and 23/31 (74.2%) had remained continuously on any 5-ASA therapy respectively. Twelve (38.7%) and 11 (35.5%) patients remained on balsalazide continuously at three and five years respectively after drug supply returned, equating to a loss of market share (within 5-ASA class) of 45.2% and 38.7% respectively. CONCLUSION: This study of a balsalazide shortage in UC patients exemplifies the detrimental impact of a drug shortage on long term patient, disease and commercial outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Eastern Health, Box Hill, Victoria 3128, Australia.
Zitieren
APA
van Langenberg, D. R., Cheng, R. K., & Garg, M. (2020). Outcomes of a drug shortage requiring switching in patients with ulcerative colitis. World Journal of Gastrointestinal Pathophysiology, 11(2), 32-42. https://doi.org/10.4291/wjgp.v11.i2.32
Vancouver
van Langenberg DR, Cheng RK, Garg M. Outcomes of a drug shortage requiring switching in patients with ulcerative colitis. World Journal of Gastrointestinal Pathophysiology. 2020;11(2):32-42. doi:10.4291/wjgp.v11.i2.32
BibTeX
@article{vanLangenberg2020,
author = {van Langenberg, Daniel R and Cheng, Richard Kai-Yuan and Garg, Mayur},
title = {Outcomes of a drug shortage requiring switching in patients with ulcerative colitis},
journal = {World Journal of Gastrointestinal Pathophysiology},
year = {2020},
volume = {11},
number = {2},
pages = {32--42},
doi = {10.4291/wjgp.v11.i2.32}
}
EUVIMED